Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 42 Carcinoma, Non-Small-Cell Lung 18 Neoplasms 15 Neoplasm Metastasis 14 Carcinoma, Renal Cell 10 Carcinoma, Hepatocellular 8 Ovarian Neoplasms 6 Colorectal Neoplasms 6 Uveal Melanoma 5 Triple Negative Breast Neoplasms 5 Small Cell Lung Carcinoma 5 Pancreatic Neoplasms 5 Mesothelioma 5 Diabetes Mellitus, Insulin-Dependent, 12 5 Carcinoma, Transitional Cell 5 Squamous Cell Carcinoma of Head and Neck 4 Sarcoma 4 Lung Neoplasms 4 Carcinoma, Merkel Cell 4 Advanced Cancer 4 Uterine Cervical Neoplasms 3 Stomach Neoplasms 3 Prostatic Neoplasms 3 Multiple Myeloma 3 Lymphoma, Non-Hodgkin 3 Lymphoma 3 Liver Neoplasms 3 Hodgkin Disease 3 Head and Neck Neoplasms 3 Carcinoma 3

Interventions

relatlimab 1 daratumumab 1 Nivolumab 1 Ipilimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Various Advanced Cancer × Ipilimumab × Clear all

NCT02488759 2023-11-13

CheckMate358

Bristol-Myers Squibb

Phase 1/2 Completed

578 enrolled 19 charts

Various Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡